Janux Therapeutics
0 followers
JANX
Performance
About Janux Therapeutics
Janux Therapeutics is a biotechnology company developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without systemic safety issues. The company focuses on precision-engineered bispecific T cell engagers using TRACTr and TRACIr modalities, along with the ARM platform, to engage the immune system in targeted ways. Its development programs center on cancer and autoimmune indications, with clinical trials such as JANX007 for prostate cancer (mCRPC) and other TRACTr-based assets. Janux positions itself as advancing targeted immunotherapies with an emphasis on safety and tumor-activated mechanisms.
Recent News
Recent Deals
No recent deals for this company.